Datavault AI (NASDAQ:DVLT) & Coeptis Therapeutics (NASDAQ:ZSQR) Financial Contrast

Coeptis Therapeutics (NASDAQ:ZSQR) and Datavault AI (NASDAQ:DVLT) are both small-cap technology companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Institutional and Insider Ownership

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 0.7% of Datavault AI shares are held by institutional investors. 24.2% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 7.7% of Datavault AI shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Coeptis Therapeutics and Datavault AI, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1	0	0	0	1.00
Datavault AI	1	1	1	1	2.50

Datavault AI has a consensus price target of $2.50, indicating a potential upside of 1,577.85%. Given Datavault AI’s stronger consensus rating and higher possible upside, analysts plainly believe Datavault AI is more favorable than Coeptis Therapeutics.

Risk and Volatility

Coeptis Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the S&P 500. Comparatively, Datavault AI has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.

Earnings and Valuation

This table compares Coeptis Therapeutics and Datavault AI”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36 million	116.91	-$11.92 million	($1.63)	-1.84
Datavault AI	$46.86 million	3.02	-$78.99 million	($0.42)	-0.35

Coeptis Therapeutics has higher earnings, but lower revenue than Datavault AI. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Datavault AI, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Coeptis Therapeutics and Datavault AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%
Datavault AI	-370.21%	-46.04%	-39.35%

Summary

Datavault AI beats Coeptis Therapeutics on 11 of the 15 factors compared between the two stocks.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

About Datavault AI

Datavault AI Inc., a data sciences technology company, owns and operates data management and supercomputer platforms. It offers data technology and software solutions. The company was formerly known as WiSA Technologies, Inc. and changed its name to Datavault AI Inc. in February 2025. Datavault AI Inc. was incorporated in 2010 and is headquartered in Beaverton, Oregon.